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Abstract: The nuclear receptors (NRs) belong to a vast family of evolutionary conserved proteins
acting as ligand-activated transcription factors. Functionally, NRs are essential in embryogenesis and
organogenesis and in adulthood they are involved in almost every physiological and pathological
process. Our knowledge of NRs action has greatly improved in recent years, demonstrating that
both their expression and activity are tightly regulated by a network of signaling pathways, miRNA
and reciprocal interactions. The Chicken Ovalbumin Upstream Promoter Transcription Factor II
(COUP-TFII, NR2F2) is a NR classified as an orphan due to the lack of a known natural ligand.
Although its expression peaks during development, and then decreases considerably, in adult
tissues, COUP-TFII is an important regulator of differentiation and it is variably implicated in tissues
homeostasis. As such, alterations of its expression or its transcriptional activity have been studied
and linked to a spectrum of diseases in organs and tissues of different origins. Indeed, an altered
COUP-TFII expression and activity may cause infertility, abnormality in the vascular system and
metabolic diseases like diabetes. Moreover, COUP-TFII is actively investigated in cancer research but
its role in tumor progression is yet to be fully understood. In this review, we summarize the current
understanding of COUP-TFII in healthy and pathological conditions, proposing an updated and
critical view of the many functions of this NR.
Keywords: NR2F2; COUP-TFII; cancer; metabolism; NF-κB; EMT; angiogenesis;
development; metabolism
1. Introduction
The nuclear receptors (NRs) belong to a family of evolutionary conserved proteins acting as
ligand-activated transcription factors. The defining features of NRs are two highly conserved domains:
the DNA binding domain (DBD) and the ligand binding domain (LBD), separated by a hinge region.
Interestingly, the DBD and LBD may function independently from one another [1,2]. The DBD domain
is necessary for the binding to DNA sequences found in the promoter regions of NR target genes,
called hormone response element (HRE), which are specific for each NR. HRE are short nucleotide
sequences usually present in pairs that are separated by a spacer of various lengths; the pairs can be in
the same orientation, as in the direct repeats (DR) HRE, or in opposed orientation, like in the inverted
(IR) HRE. The LBD instead recognizes and binds the ligand, usually small hydrophobic molecules like
retinoids, vitamins and lipophilic hormones, but also xenobiotics or antibiotics [3].
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The ligand induces a conformational change of the NR molecule necessary to modify the binding
properties of the receptors and the affinity for co-repressors or co-activators. HRE bound and unbound
NRs act as monomers, homodimers or heterodimers (usually with retinoid X receptor, RXR) in the
target promoter.
Initially identified in 1985 [4], the NRs are classified according to their evolutionary distance in six
subfamilies, numbered from 1 to 6; each subfamily is further divided in several groups (indicated by
letters, starting with A), followed by a number to indicate the specific member. A seventh family of
NRs, NR0, has been introduced to identify NRs missing the DBD [1,3].
NRs are also classified according to the existence of known ligands and their mode of action and
functional status before the ligand binding. Some of the NRs were isolated and characterized after
the identification of their ligand (i.e., the endocrine NRs); however, roughly half of the 48 NRs have
been isolated without previous knowledge of their ligand and were classified as “orphan”, meaning
that a specific ligand was missing. The existence of orphan receptors had important implications
for endocrinology research, paving the way towards the “reverse endocrinology” concept [5]. The
“reverse endocrinology” concept represents a substantial paradigm shift in endocrinology: Before the
identification of orphan receptors, new hormones were discovered and isolated, and their physiological
effects studied and subsequently used to identify their receptors; conversely, in “reverse endocrinology”
the ligand discovery is driven by the identification of their receptors and it often uncovered previously
unknown and unexpected signaling pathways. RXR was the first of the “orphan” receptor for whom
its specific natural ligand, 9-cis-retinoic acid (9-cis-RA), was identified; all orphan NRs with identified
ligands are indicated as “adopted”. Adopted NRs are, for example, Farnesoid X receptor (FXR), liver X
receptor (LXR), peroxisome-proliferator activated receptors (PPARs) and hepatocyte nuclear factor 4
(HNF4) [1].
The NRs mode of action (and functional status before the binding of the ligands) distinguishes
NRs in four classes or types: type I NRs are complexed with heat shock proteins (HSP), reside in the
cytosol before binding the ligands and work as dimers recruiting co-activators; type II receptors work
as heterodimers, reside in the nucleus bound to the DNA with co-repressors in the absence of the
ligands; type III NRs work essentially as homodimers; and, finally, type IV NRs are poorly studied and
bind to HRE preferentially as monomers [3].
Functionally, NR activity is essential during development and the adult life and NRs are involved
in almost every physiological process (e.g., cell commitment and differentiation, organ development,
regulation of metabolism). Given the broad range of NR functions, it is not a surprise that their altered
activity has been linked to the development of human diseases.
2. COUP-TFII: An Overview on Structure, Mechanism of Action and Expression
Chicken Ovalbumin Upstream Promoter Transcription Factors (COUP-TFs) are orphan NR
transcription factors belonging to subfamily 2 (NR2) group F of the NR family [1,3,6].
In vertebrates, three homologous subtypes were identified: COUP-TFI (EAR-3, NR2F1),
COUP-TFII (ARP-1, NR2F2) and COUP-TFIII (EAR-2, NR2F6) [7–11].
The main human isoforms of COUP-TFI, II and III are similar in length, ranging from the 404
amino acids (AA) for COUP-TFIII to the 423 AA of COUP-TFI. The COUP-TFs proteins share the six
regions structure of NRs (from N-terminal to C-terminal): the A/B region containing the activating
function 1 (AF1), necessary for the recruitment of co-activators; the C region with the DBD; the hinge
or D region that probably double as the nuclear localization sequence (NLS); the E region with the
AF-2 and the LBD; and followed by the F or C-terminal region (Figure 1A).
COUP-TFI and II NRs have the highest homology among the COUP-TFs, especially in the DBD
and LBD, whereas homology in the N-terminal is around 50% [12]. Indeed, homology is 98% in the
N-terminal DBD and 96% in C-terminal LBD [10]; interestingly, homology in the N-terminal AF-1 is
only around 50%. Instead, COUP-TFIII is more divergent, suggesting that the separation of COUP-TFIII
from COUP-TFI/COUP-TFII is an early evolutionary event in the history of the NR2F group (Figure 1B).
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(guide tree) with cladogram branch length of the NR2F family showing that separation of COUP-
TFIII from COUP-TFII and COUP-TFI is probably an early evolutionary event (data obtained from 
ClustalOmega alignment of human NR2F1, NR2F2 and NR2F6). Based on References [1–3]. 
2.1. COUP-TFI and COUP-TFII: Similarities and Differences 
Both COUP-TFI and COUP-TFII show an elevated degree of evolutionary conservation and this 
suggests their crucial role in cellular function; moreover, their high homology could be indicative of 
redundancy and of overlapping functions. Nonetheless, the two receptors are in distinct loci, and 
regulate different physiological functions; these differences may be ascribed to differences in the 
regulation of gene expression associated with distinct positions in the genome and with a dissimilar 
affinity for co-activators and co-repressor that are recruited by AF-1, a region of low homology 
between the receptors. 
Specifically, the COUP-TFI gene is located on chromosome 5 in humans and on chromosome 13 
in mice [13]. It is expressed predominantly during the development of the peripheral nervous system 
(PNS) and the central nervous system (CNS) and it is involved in early neurogenesis [12,14]. 
Interestingly, COUP-TFI knock out (KO) is lethal in perinatal life but not during embryogenesis, with 
defects localized mainly in the central nervous system (CNS) [15]. Instead, the NR2F2 gene encoding 
for COUP-TFII is located on chromosome 15q26 in humans and on chromosome 7 in mice [13]. The 
gene is organized in three exons, plus a newly identified exon in the 5′ of the putative COUP-TFII 
promoter. The NR is mainly expressed in mesenchymal cells during organogenesis and is 
indispensable for normal development. In fact, COUP-TFII KO mice show several vascular 
abnormalities in the heart and brain, and they die around the tenth day of embryonic life, while two-
thirds of heterozygous mice die during the first week of life [16]. Despite the COUP-TFII influence in 
several aspects of embryogenesis, its expression declines dramatically until reaching basal levels in 
adult healthy tissues. 
In the adult, an increase in COUP-TFII expression occurs under pathological conditions, such as 
cardiovascular diseases [17] or cancer, in which it regulates tumor growth and metastasis by 
modulating tumor angiogenesis [3,18]. 
The expression pattern of COUP-TFI and COUP-TFII have been thoroughly reported elsewhere 
(see [12,19–22] for reviews). 
2.2. COUP-TFII Signaling: Activation, Repression and Transrepression 
NRs control gene transcription by one of several mechanisms. Activation of target genes can be 
direct (a consequence of a direct binding to HRE), indirect (when the NR acts as an accessory factor) 
or coming from a protein–protein interaction. Similarly, repression by NR can be direct (or active) or 
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possess the typical features of the NR domain structure of COUP-TFs nuclear receptor (NR). (B)
Phylogram (guide tree) with cladogram branch length of the NR2F family showing that separation of
COUP-TFIII from COUP-TFII and COUP-TFI is probably an early evolutionary event (data obtained
from ClustalOmega alignment of human NR2F1, NR2F2 and NR2F6). Based on References [1–3].
2.1. COUP-TFI and COUP-TFII: Similarities and Differences
Both COUP-TFI and COUP-TFII show an elevated degree of evolutionary conservation and this
suggests their crucial role in cellular function; moreover, their high homology could be indicative
of redundancy and of overlapping functions. Nonetheless, the two receptors are in distinct loci,
and regulate different physiological functions; these differences may be ascribed to differences in the
regulation of gene expression associated with distinct positions in the genome and with a dissimilar
affinity for co-activators and co-repressor that are recruited by AF-1, a region of low homology between
the receptors.
Specifically, the COUP-TFI ge l cated on chromosome 5 in humans and on chromosome
13 i ice [13]. It is expr ssed predominantly during the dev lopment of t peripheral nervous
system (PNS) and the central nervous system (CNS) and it is in olved in early neurog nesis [ 2,14].
Interestingly, COUP-TFI knock out (KO) is lethal i i t l life but not during embryogenesis, with
defects localized mainly in the central nervous system (CNS) [15]. Instead, the NR2F2 gene encoding for
COUP-TFII is located on chromoso e 15q26 in humans and on chromosome 7 in mice [13]. The gene
is organized in three exons, plus a newly identified exon in the 5′ of the putative COUP-TFII promoter.
The NR is mainly expressed in mesenchymal cells during organogenesis and is indispensable for
normal development. In fact, COUP-TFII KO mice show several vascular abnormalities in the heart
and brain, and they die around the tenth day of embryonic life, while two-thirds of heterozygous
mice die during the first week of life [16]. Despite the COUP-TFII influence in several aspects of
embryogenesis, its expression declines dramatically until reaching basal levels in adult healthy tissues.
In the adult, an increase in COUP-TFII expression occurs under pathological conditions, such as
cardiovascular diseases [17] or cancer, in which it regulates tumor growth and metastasis by modulating
tumor angiogenesis [3,18].
The expression pattern of COUP-TFI and COUP-TFII have been thoroughly reported elsewhere
(see [12,19–22] for reviews).
2.2. COUP-TFII Signaling: Activation, Repression and Transrepression
NRs control gene transcription by one of several echanis s. Activation of target genes can be
direct (a consequence of a direct binding to ), in irect ( hen the NR acts as an accessory factor)
or coming from a protein–protein interaction. i il l , sion by NR can be direct (or active) or
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indirect (or passive) (e.g., competition for RXR heterodimerization) or obtained after direct binding to
other NRs in a process called transrepression (Figure 2).
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Figure 2. COUP-TFII dimerization and mechanism of action. COUP-TFII may form homo- and
heterodimers and may act as a transcriptional repressor or activator, in a cell-dependent manner.
Natural ligands for COUP-TFII are unknown, but the NR may be activated by a high concentration of
9-cis-RA and inhibited by naphthol compounds. Based on References [3,23–33].
Even if COUP-TFs were originally identified as transcriptional activators of the chicken ovalbumin
gene [34], COUP-TFII can serve as a transcriptional activator or repressor in a cell-type-dependent and
gene-specific manner through binding to AGGTCA DR [23]. It has been shown to interfere with the
transactivation of other nuclear hormone receptors (e.g., PPAR, VDR, TR and RAR) through the direct
occupation of their DNA-binding site or the sequestration of RXR [23–27].
RXR is the heterodimeric partner of choice of a multitude of NRs and is able to bind to orphan
NRs increasing their transactivation potential [28,35,36]. In homodimers, RXR responds exclusively
to 9-cis-RA, but it can form a heterodimer, for example with PPARs, thus becoming able to bind
PPAR-specific ligands. Although COUP-TFII may bind DNA as a homodimer, it forms stable
DNA-binding heterodimers with RXR and other NR and transcription factors [24,25,29]. When
sequestered by COUP-TFII, RXR is no longer available to bond with other NRs, thus interfering with
the transactivation of their target genes [24,27].
Moreover, COUP-TFII can act as a transcripti nal i hibitor thanks to the recruit ent of
co-repressors. Its interaction with th sil nci g m di tor for retinoic acid receptor and thyroid
hormo e receptor (SMRT) i hibits PPARγ gene expression, necessary for ad pocyte differen ation, in
a Wnt/β-cat nin pathway depende t mann r [30]. I addition, COUP-TFII can also inhibit transcription
by transrepression, by directly binding to the LBD of nuclear hormone receptors [31].
COUP-TFII is a positive regulator of the transcription of several genes by binding to DNA elements
and directly or indirectly activating gene expression. For example, it acts synergistically with HNF4
to activate the rat cholesterol 7α-hydroxylase (CYP7A1), which catalyzes the first step in the bile
acid synthesis pathway [37]. Moreover, COUP-TFII (physically interacting with HNF-4) can increase
the activation of the HNF-1α gene promoter in the liver if compared to that determined by HNF-4
alone [38]. Despite these pieces of evidence of a synergistic interaction between COUP-TFII and HNF-4,
it has been shown that COUP-TFII is also able to act differently by inhibiting HNF-4 transactivation
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according to a different promoter context [39], confirming the dual role that this receptor plays in
a context-dependent manner.
2.3. COUP-TFII Protein Structure: Isoforms, the LBD and the Ligands
The existence of COUP-TFII isoforms has been acknowledged only recently [40,41]. While the NR
primary isoform has the structure described above, at least one other isoform has been discovered in
mice, while three more have been found in humans (one of these is the orthologue of the second mouse
isoform, identified as variant 2, or V2). All these newly identified isoforms are shorter than the canonical
COUP-TFII (COUP-TFII variant 1, COUP-TFII_V1) and they have in common a different N-terminal
region that may originate from the use of the alternative first exon cited above (in mice and humans)
or, in humans only, by protein translation beginning inside the second exon. All these isoforms miss
the DBD but have the same LBD of the COUP-TFII_V1, casting doubts on their function as standard
NRs. Indeed these new isoforms have been demonstrated to either increase or decrease canonical
COUP-TFII activity in a cell-dependent manner: In hepatocellular carcinoma cells, COUP-TFII_V2
reduces the ability of COUP-TFII_V1 to activate CYP7A1, while in human embryonic stem cells they
have been show to increase the activity of the longest isoform [40,41]; given the lack of a DBD, we may
hypothesize that they might compete for the binding of co-repressors or co-activators, but how they
truly act is still unknown.
In an effort to identify putative ligands for COUP-TFII, Kruse et al. [32] focused their attention
on the human COUP-TFII LBD, demonstrating a peculiar auto-inhibited disposition in the crystal
structure [32]. Usually, the NR activity is mainly guaranteed by the conformational states of the AF-2
helix, located in the LBD region [42]. The binding of an agonist ligand stabilizes the AF-2 in an active
conformation that makes the LBD able to recruit co-activator proteins. In contrast, antagonist ligands
promote an inhibited conformation of the LBD region [43]. Instead, for COUP-TFII in the absence of
ligands, the auto-repressed conformation is due to the interaction between the AF-2 and the co-factor
binding site, which physically prevents the recruitment of co-activator or co-repressor proteins [32].
These pieces of evidence suggest a mechanism in which ligands activate COUP-TFII through the
release of the receptor from its auto-inhibited state, even if a physiological ligand capable of inducing
the activation of COUP-TFII has not yet been identified.
The absence of a classical ligand-binding pocket highlighted by the crystallographic analysis of
the COUP-TFII structure reveals that this is probably a true orphan receptor [32]. Despite this, it is
possible to claim that COUP-TFII is a ligand-regulated NR since its activity can be modulated by high
concentrations of retinoid acids [32], as well as chemicals belonging to the naphthol family [33]; of
interest is whereas retinoic acid activates COUP-TFII, synthetic naphthol compounds are inhibitory.
Naphthol compounds are small polycyclic molecules characterized by the presence of the phenyl ring;
they have been shown to interact with a small hydrophobic surface pocket in the LBD that is away
from the putative interacting surface with co-activators. Surprisingly, the naphthol compounds do not
inhibit the co-activators’ binding. Instead they determine a proteasome-independent degradation of
the NR. Indeed, the naphthol analogues’ binding is believed to induce autophagy of COUP-TFII as
evidenced by the formation of NR foci, especially in the cytosol [33].
3. Regulation of Cell Differentiation and Cell Function in Health
3.1. Mesenchymal/Stromal Cells Identity
Experimental pieces of evidence suggest that a time-specific and balanced expression of COUP-TFII
is a general mechanism of regulation of cell differentiation as demonstrated, for example, by the role of
the nuclear receptor in neurogenic-to-gliogenic stemness [44], in muscle or renal differentiation and in
mesenchymal commitment and differentiation [20,45–47].
Cells 2020, 9, 101 6 of 30
COUP-TFII is highly expressed in differentiating and adult mesenchymal cells and its expression
influences cells terminal differentiation and fate choice, a function strongly associated to the regulation
of stemness.
Hepatic and pancreatic stellate cells (HSC and PSC, respectively), as their names suggest, are
cells residing in the liver and pancreatic parenchyma [48–51]. While HSC have been extensively
investigated, studies on PSC are, in comparison, limited; nonetheless, HSC and PSC are substantially
identical in function and the minimal differences in gene expression between them are probably due to
the different micro-environment; hence, the knowledge on HSC functional role and differentiation are
likely applicable to PSC. HSC are lipid accumulating cells located in the space of Disse and their main
feature is the presence of vitamin A droplets. HSC, after cytokine stimulation, become “activated”
and undergo a dramatic change of phenotype acquiring a myofibroblast-like phenotype and become
pro-fibrogenic cells, expressing α-smooth muscle actin [52,53]. The transition between the quiescent
and the activate state is apparently driven by COUP-TFII. The expression of PPARγ is necessary
for lipid metabolism and for the preservation of the quiescent state; conversely, after activation by
PDGF or TGF-β, HSC start expressing COUP-TFII while simultaneously reducing PPARγ expression.
Interestingly, the alternative expression of COUP-TFII and PPARγ and the regulation of PPARγ activity
(in the specific case of HSC, the suppression of its transcriptional activity) might be considered a general
mechanism of cell specification for stromal cells (see below for bone stromal cells and adipocyte
differentiation). Moreover, similar to endothelial cell differentiation, HSC COUP-TFII is downregulated
by activation of the Notch pathway, suggesting that Notch-mediated inhibition of COUP-TFII might
be another common mechanism of genetic regulation, which, together with Hedgehog (HH) signaling,
may be important in cell fate decision and in sensing tissue integrity [54].
COUP-TFII is implicated in cell fate decision of bone marrow stromal cells (BMSC) and is
necessary in the early phases of adipose differentiation of C3H10T1/2 cells and BMSC. Specifically,
in BMSC, COUP-TFII is apparently pivotal for directing towards adipocyte, osteoblast, chondrocyte
or myoblast differentiation, which are mutually exclusive specification routes. Molecular analysis
performed to identify the drivers of these process show that COUP-TFII downregulates β-catenin
and RUNX-dependent genes [55]. RUNX, a master regulator of bone development, may form dimers
with COUP-TFII, and COUP-TFII/RUNX complexes are less efficient in activating RUNX-osteoclastic
genes [56]. By blocking Wnt and RUNX2 and activating PPARγ, COUP-TFII induces pre-adipocytes
commitment of BMSC whilst COUP-TFII-mediated activation of SOX9 allows the preferential
development of chondrocytes and suppress pre-myoblast commitment [55]. Expression of COUP-TFII
in osteoblast/adipocyte cell decision is under the control of miRNA 194 and fibroblast growth
factor 2 (FGF2) [57,58]. miR-194 and FGF2 act in opposition: In the presence of osteogenic stimuli,
miR-194 expression increases and, targeting COUP-TFII, induces osteogenic differentiation; conversely,
the extracellular stimulation of FGF2 counteracts the effect of miR-194 increasing COUP-TFII expression
through the MEK1/2 signaling pathway, further demonstrating its crucial role for the integration of
signals determining cell differentiation.
The pivotal role of COUP-TFII in differentiation is also demonstrated by its interaction and
reciprocal regulation with stemness factors, primarily OCT4. In undifferentiated cells, COUP-TFII
transcription is actively repressed by OCT4. Interestingly, OCT4 allows the expression of the
COUP-TFII-repressor miR-302. Hence, OCT4, directly and indirectly suppressingCOUP-TFII, maintains
the pluripotency of stem cells; conversely, when COUP-TFII expression and activity increases, such as
during the initial commitment, OCT4 is repressed. Repression of OCT4 is COUP-TFII-dependent and
requires the binding of COUP-TFII to the OCT4 promoter. Interestingly, expression of COUP-TFII is
self-sustained by a positive feedback loop, indicating that the expression of NR, once induced by still
unknown mechanisms, inexorably leads to commitment and differentiation [41,59].
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3.2. COUP-TFII in Metabolism and Metabolic Active Organs
COUP-TFII expression in metabolic tissues has been described since 2002 [60] and some of its
functions and mechanisms of action has become clearer since then. COUP-TFII not only regulates
energy expenditure in local tissues but it is also implicated in pancreatic insulin secretion and central
nervous system response to available energy substrates.
3.2.1. COUP-TFII, Energy Expenditure and the White Adipose Tissue
COUP-TFII expression is inversely associated to energy expenditure in metabolic organs.
Heterozygous COUP-TFII +/−mice have a liner body, reduced gain of body weight, comparable brown
adipose tissue (BAT) but reduced white adipose tissue (WAT) [61]. Interestingly, COUP-TFII +/−mice
have increased glucose tolerance and glucose homeostasis that could be a consequence of increased
energy expenditure and better glucose metabolism. The increased energy expenditure is probably
associated to higher expression of uncoupling protein 1 (UCP1) and PPARγ co-activator 1α (PCG1α)
and agree with the phenotype of COUP-TFII over-expressing mice in the heart that show a reduced
metabolism, increased ROS production and altered mitochondria [17]. The reduced accumulation of
WAT tissue points to a role of COUP-TFII in adipose differentiation. Indeed, silencing COUP-TFII in
differentiating adipocytes reduces the accumulation of lipid droplets caused by a COUP-TFII-mediated
inhibition of Wnt10 synthesis. Similarly, Okamura et al. [30] demonstrated that COUP-TFII is
necessary for adipocyte differentiation: in 3T3-L1 preadipocyte cells, β-catenin induces the expression
of COUP-TFII that then recruits the SMRT co-repressor to the PPARγ promoter, suppressing the
expression of the master regulator of adipogenesis. The apparent discordance in the conclusions of the
two papers might be explained by the observation that COUP-TFII expression increases in the initial
phase of differentiation and precedes the expression of PPARγ, suggesting that COUP-TFII expression
is necessary for the proliferation and commitment of pre-adipocytes [30]. Interestingly, by modulating
PPARγ and adipocyte differentiation, COUP-TFII could influence the onset of obesity and diabetes [51].
The COUP-TFII-glucose link in metabolism is further confirmed by the finding that the
overexpression of the NR increases lactate production in response to MEK activation. Lactate
then activates the mTORC1 and further influences cell metabolism. Increased lactate production by
lactate dehydrogenase activation is a hallmark of the Warburg effect and could be associated with
an increased epithelial to mesenchymal transition (EMT) and with cancer progression [62].
3.2.2. COUP-TFII and Liver Metabolism
In the liver, COUP-TFII is implicated in the control of fatty acid β-oxidation and glucose
metabolism. The NR PPARα is the main regulator of fatty acid metabolism in the liver; it controls fatty
acid β-oxidation and transport, and its expression is regulated by two NRs (HNF4α and COUP-TFII)
that are caught in a regulatory loop. HNF4α and COUP-TFII receptors bind to the PPARα promoter
with opposite effects on the same HNF4α-HRE: While HNF4α is a PPARα inducer, COUP-TFII binding
to HNF4α-HRE reduces basal and HNF4α-induced PPARα expression, hence acting as a repressor [63].
Interestingly COUP-TFII expression is positively regulated by HNF4α (but the ability of the latter
to induce COUP-TFII is reduced by high glucose concentrations) and PPARα binds to HNF4α-HRE,
positively regulating its own expression [64].
COUP-TFII interacts with glucocorticoid receptorα (GRα) for the expression of CYP7A1, while the
interaction of COUP-TFII with the GRα response elements repress the expression of GRα-activated genes
by recruiting co-repressors [65]. Interestingly, the dimerization with GRα is necessary for the activation
of the liver phosphoenolpyruvate kinase, the rate limiting enzyme of liver gluconeogenesis [65,66].
Bile acids are necessary for nutrients absorption but they also act as signaling molecules [67];
they stimulate cell metabolism and protect the liver from inflammation and steatosis, activating
G-protein coupled receptors and FXR. As previously stated, CYP7A1 is the rate-limiting enzyme for
bile acid synthesis from cholesterol and its expression is regulated directly by COUP-TFII, clearly
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suggesting that the NR may indirectly influence hepatic metabolism, regulating bile acid synthesis.
Bile acids are the natural ligands of FXR that indirectly counteract the COUP-TFII-mediated activation
of CYP7A1. Indeed, activated FXR increases the expression of the small heterodimer protein (SHP),
a nuclear receptor belonging to the NR0 family, that sequesters LRH-1, an obligated factor for CYP7A1
expression [68].
In the liver and pancreas, glucose repression of COUP-TFII is modulated by insulin. Binding of
insulin to its receptor activates the AKT pathway, which in the end brings forth the phosphorylation
and nuclear exclusion of FOXO1 and COUP-TFII repression [69]. Moreover, hyperglycemia induces
the ChREBP-mediated COUP-TFII downregulation, resulting in lipogenesis and glycolysis [69].
In newborn mice,COUP-TFII mRNA steadily increases and theNR2F2 gene expression is enhanced
directly by PPARα and indirectly, via cAMP, by glucagon. Newborn mice infected with a dominant
negative COUP-TFII have impaired gluconeogenesis associated with a reduction in co-factors for
fatty acid oxidation. Rescuing the PPARα activation with agonist Wy 14,643, Planchais et al. have
hypothesized that COUP-TFII and PPARα co-operate for the regulation of β-oxidation and that
COUP-TFII is necessary for the maintenance of correct glucose levels by gluconeogenesis in newborn
mice [70].
The gene of the anabolic enzyme glucokinase is another COUP-TFII target; this kinase is induced
by insulin and retinoids, and RARα, HNF4α and COUP-TFII cooperate to induce its expression [71].
3.2.3. COUP-TFII and Insulin
COUP-TFII is a mediator of insulin secretion in pancreatic β-cells [72]. In pancreas, COUP-TFII
is expressed in the endocrine compartment and β-cell-specific KO of COUP-TFII is lethal [73].
Interestingly, COUP-TFII +/−mice appear healthy but have a lower glucose tolerance associated with
decreased insulin secretion after glucose stimulation, and they show a mild increase of insulin levels
during fasting [73]. As previously cited, insulin represses COUP-TFII in peripheral tissues. Similarly,
β-cells glucose-stimulated insulin secretion suppresses COUP-TFII in an autocrine manner trough
a FOXO1-mediated mechanism, in an auto-regulatory feedback loop [69,74] (Figure 3).
Interestingly HFN4α (whose inactivation causes the maturity onset diabetes of the young 1
(MODY1) [75]) and COUP-TFII are reciprocally inducing each other whilst COUP-TFII auto-inhibits its
expression in β-cells, providing a further layer of regulation for insulin secretion [64,74].
Besides the role of insulin regulation in β-cells, COUP-TFII is also important in their homeostasis;
COUP-TFII KO in PDX1 expressing cells results in glucose intolerance and inβ-cell reduction, essentially
due to a reduced differentiation of progenitor cells. Mechanistically, β-cell homeostasis is maintained
by a COUP-TFII-mediated increase of β-catenin expression and transcriptional activity. Moreover,
induction of cyclin D1 and axin by glucagon-like peptide (GLP) (an intestinally produced hormone that
induces insulin secretion in β-cells [76]) in COUP-TFII KO mice is reduced, suggesting that COUP-TFII
is required for GLP β-catenin activation [77].
COUP-TFII is expressed at different intensities in the CNS areas (ranging from completely absent
to strongly expressed [78,79]) that are believed to contribute to the patterning and function of the
CNS [80]. Interestingly, COUP-TFII could also influence the CNS response to nutrients. Indeed, some
of the neurons of the ventromedial hypothalamus, a region pivotal for the regulation of the energy
balance, express the NR. Fed mice have higher COUP-TFII expression in the hypothalamus compared
to fasted mice, and insulin, conversely to peripheral tissues, induces the expression of the receptor in
this CNS area. Moreover, the fraction of ventromedial hypothalamic neurons expressing COUP-TFII
are also positive for the steroidogenic factor 1 (SF1), a protein specifically expressed in neurons involved
in energy sensing. In the ventromedial hypothalamus, SF1 is co-expressed with the melanochortin
receptor, whose ligand is secreted in response to insulin. Interestingly, melanochortin receptors with
the intermediation of cAMP induce COUP-TFII. The difference in insulin effects on COUP-TFII in the
CNS compared to peripheral tissues are likely a consequence of insulin acting as an anabolic factor
for the liver or the adipose tissue and catabolic in the central nervous system [81]. In agreement with
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this observation, COUP-TFII +/−mice in the ventromedial neurons display a liner phenotype, with
increased energy expenditure, and are more prone to develop hypoglycemic-associated autonomic
failure [82].
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Figure 3. COUP-TFII and insulin in pancreatic β-cells. High glucose concentrations in the blood induce
the release of insulin by β-cells and attenuate the expression of COUP-TFII. COUP-TFII is known to
repress insulin genes, hence reducing the expression of COUP-TFII increases insulin gene expression
but reduces insulin secretion. Interestingly, insulin in a paracrine manner further decreases COUP-TFII
expression by nuclear exclusion of FOXO1 caused by AKT-mediated phosphorylation. HNF4α and
COUP-TFII are reciprocally induced and sustain insulin secretion. Based on References [69,72–74].
3.3. The Vein Identity and the Link to NOTCH
The observation thatCOUP-TFII KO mice show defects in angiogenesis, specifically in the appearance
of venous and lymphatic vessels, prompted several groups to study the angiogenesis–COUP-TFII link [16].
Blood vessels arise early during embryogenesis to compensate for the increasing need of nutrients
and oxygen of the growing and differentiating organs. Vasculogenesis, the de novo formation of
blood vessels in embryo, is different from angiogenesis [83–85]. Whereas angiogenesis is the formation
of blood vessels from existing ones, vasculogenesis is the process of differentiation of angioblasts
as they coalescence to form the primitive vessel bed and is limited to the embryonic phase. After
vasculogenesis, the first signs of arterial specification appear around day E8.5 with major morphological
changes (e.g., the initial heart formation) between day E8 and E9. Venous and lymph markers appear
later, usually after day E9–9.5 [85]. Despite the different morphology origin, vasculogenesis and
angiogenesis are regulated by similar mechanisms with major players being the Notch signaling
pathway and VEGF; other pathways involved are BMP/TGF-β and Hedgehog (HH) [84,85].
The Notch pathway is a cell-to-cell contact pathway that requires the presence of the
membrane-bound Notch ligands Jagged and Dll in one cell, and the trans-membrane Notch receptors
in the adjacent cells; the cells receiving the Jagged or Dll signal cleaves the Notch receptor, which
ultimately determines the transcription of the Notch effectors Hes and Hey. Notch acts through lateral
inhibition, a termed coined in neuroscience to describe the ability of an active neuron to reduce the
firing of the neighbor cells. Notch lateral inhibition is a frequent phenomenon and it is fundamental
for maintaining the intestinal architecture [86]. The steps necessary to activate the pathway and the
underlying mechanisms have been extensively studied (for recent reviews see [86–88]).
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During angiogenesis, vessel cells naturally develop towards the venous phenotype whereas
Notch signals direct the cells toward the artery phenotype. Indeed, expression of the intracellular
Notch receptor induces the expression of endothelial markers and arterial marker ephrin B2 and Nrp1
in normal differentiating cells and in endothelial cells after ischemia [89]. Conversely, KO mice for
components of the Notch pathways die in utero due to defects in vessels morphogenesis [90,91]. In
this process Notch appear pivotal in inducing cell differentiation but Notch expression is dispensable
for cell proliferation.
Besides Notch, differentiating cells receive paracrine signals mainly by VEGF. Activation of
VEGF Receptor 2 (VEGF-R2) by VEGF A and D induces the appearance of ephrin B and increases the
expression of Dll-4. VEGF release in the extracellular matrix is controlled by HH paracrine secretion
given that null mutants for HH do not express ephrin B2 [85]. The expression of Notch ligands in
response to VEGF appears to be important during vessel sprouting and in the maintenance of the tip
and stalk vessel growth. Tip cells express Dll-4 at high levels and induce the activation of Notch in
the stalk cells, committing them to the arterial phenotype; at the same time, Notch reduces Dll and
VEGF-R2 expression, suggesting that both pathways are strictly intertwined.
Starting from embryonic day 8, COUP-TFII expression in mice is detectable in the visceral
mesoderm and differentiating heart [16]. General knock out of the receptor is lethal in utero (no mice
are alive after E10) and it is associated with vast edema and hemorrhages in the brain and heart;
a small percentage of haplo-insufficient mice show defects similar to what is observed in full KO mice,
suggesting that even a partial reduction of the nuclear receptor is sufficient to induce the observed
phenotype [14,16].
Expression of COUP-TFII induces vein genes expression (e.g., the receptor ephrb4) and later on
lymphatic vessel specification (Figure 4).
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C P-TFII is related to both the VEGF and Notch pathway. Indeed, RIP-tag mice KO of COUP-TFII
reduces insulinoma growth due to altered angiogenesis [18]; the observed phenotype is associated
with a loss of repression of the decoy receptor VEGF-R1, an inhibitor of VEGF-R2 signaling. Moreover,
COUP-TFII receptor controls angiopoietin expression in pericytes [92]. COUP-TFII blocks the Notch
pathway, acting both upstream and downstream of Notch; upstream, COUP-TFII directly binds and
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reduces the expression of FoxC1 and NP-1, whereas downstream it binds to Hey2 [93]. The KO of
FoxC1, a member of the Forkhead/Fox transcription factor family, reduces the expression of Dll-4 and
NP-1, a co-receptor of VEGF-R2, and increases the expression of the lymphatic marker Lyve1. Moreover,
KO of FoxC1 and 2 reduces lymphatic sprouting due to lower VEGF-C expression [93]. Anyway,
in the Notch pathway COUP-TFII is essentially a repressor of the transcription of artery-specific
genes. In agreement with this hypothesis, endothelial cells with reduced COUP-TFII expression show
alteration of G1/S progression, lower proliferation and higher expression of artery markers, all effects
consistent with Notch activation; conversely, COUP-TFII in endothelial cells increases cell sprouting
and cell proliferation, which is mediated by an increased expression of E2F1 that is regulated by both
COUP-TFII and SP1 [100,101].
Endothelial progenitor cells (EPC) have high expression of vein markers (e.g., COUP-TFII)
and low expression of arterial markers (e.g., Dll-4 and Hey2), at least in the vein patch [102,103].
The oxygen sensor HIF1α induces Dll-4 and Hey2 expression in EPC in hypoxia that leads to reduction
of COUP-TFII expression [103]. Interestingly, Hey2 reduces HIF1α-mediated gene expression, creating
a negative feedback loop and indicating that oxygen availability is another factor influencing the fate
decision of endothelial cells modulating COUP-TFII and NOTCH expression [103].
Besides blocking Notch signaling, COUP-TFII actively induces vein and lymph node identity,
regulating the expression of VEGF-C and D, as well as VEGF-R3 and NP-2 [94,95]. Expression of
COUP-TFII in vein cells appear to depend on the transcription factor brahma-related gene 1 (BRG1) [96],
a chromatin-remodeling factor whose presence in the promoter is required for COUP-TFII expression.
Interestingly, BRG1 expression is also required for expression of Notch ligands [97,98]. Finally,
COUP-TFII expression is directly regulated by E26 transformation specific 1 (ETS-1), a transcription
factor belonging to the ETS family of transcription factor. ETS factors are involved in the regulation
of angiogenesis, extracellular matrix remodeling and inflammation; they may also regulate cell
metabolism and are involved in cancer progression [104–106]. ETS-1, along with the ETS factor ETV1,
binds to the COUP-TFII promoter, increasing the NR expression, and suggesting that ETS angiogenesis
is partially mediated by COUP-TFII [99].
Lymphatic vessel specification requires the expression of the transcription factor Prospero
homeobox protein 1 (Prox1) that is detectable during development around day E9.5 in the cardinal
vein [85]. Sustained expression of Prox1 is necessary to maintain lymphatic identity in the adult,
and Prox1 null mice do not develop lymphatic structures [107]. The transcription factor SRY-related
gene Sox18 is expressed before Prox1 and is required but not sufficient for the Prox1 expression
in developing embryos. Instead, COUP-TFII cooperates with Sox18 to induce Prox1 expression in
vein cells [108]. COUP-TFII directly binds to a conserved region within the Prox1 promoter and
it forms heterodimers with Prox1 [108,109]. Whereas COUP-TFII homodimers suppress the Notch
pathway, Prox1/COUP-TFII dimers lack this ability resulting in a partial expression of Notch effectors
in lymphatic vessels. Moreover, the heterodimers are permissive for the expression of lymph markers,
such as VEGF-R3 (which binds VEGF-C), and they induce the expression of cyclin E1 [29,109–111]. In
agreement with their role in lymphatic specification, COUP-TFII and Prox1 are suppressed by Hey1
and Hey2. Interestingly, the expression of Notch effectors transforms lymph cells in arterial-like cells,
suggesting that the former are extremely plastic cells that, depending of the external stimuli, may give
rise to all type of endothelial cells. This hypothesis is sustained by co-expression of all the three master
regulators of endothelial specification in lymph cells (i.e., Notch, COUP-TFII and Prox1) [112].
4. COUP-TFII in Human Pathology
It is not surprisingly that COUP-TFII is linked to the development of several pathologies.
The pathological role of COUP-TFII mirrors its function in health and is linked to, but not limited to,
the regulation of cell metabolism, cell differentiation and, in cancer, to the regulation of the tumor
micro-environment, especially angiogenesis.
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4.1. COUP-TFII in Non-Cancer-Related Pathologies
4.1.1. Cardiovascular Diseases
The overexpression of COUP-TFII, or the absence of its expression, is linked to the development of
cardiovascular diseases, specifically arteriosclerosis and congenital heart defects (CHD). It is well known
that arteries have a greater response to atherosclerosis factors compared to veins [113]; the reasons for
such an epiphenomenon is not yet clear but could be caused by COUP-TFII. As documented before,
endothelial cells of the vein and lymph vessels continue to express COUP-TFII. Interestingly, vein cells
silenced for COUP-TFII and treated with angiotensin II have higher expression of atherogenic and
inflammatory genes and downregulation of anti-thrombotic genes whilst the receptor overexpression
has opposite effects [114,115]. The reduced susceptibility to atherosclerosis cannot be explained
only on the basis of hemodynamic flow, which contribute to vascular remodeling [114,116]. Indeed,
the available data suggest that COUP-TFII expression could protect the vein from atherosclerosis by
a mechanism not yet clear but probably linked to the regulation of inflammation and lipid metabolism.
Deletions in chromosome 15q, the locus of COUP-TFII, are associated with abnormal facial
appearance, in utero and postnatal growth retardations, as well as CHD. Mapping a 5.8 Mb deletion
in a patient with CHD, Nakamura et al. [117] identified COUP-TFII as a putative candidate gene.
Association of COUP-TFII to CHD was later confirmed by other groups [118–122]. Interestingly, deletion
of 15q is not the only possible mutation happening in CHD in the COUP-TFII locus but single point
missense mutations of the NR are sufficient to induce the pathogenic phenotype [120,122]. Recently,
hyper-methylation of the promoter has been associated with the development of the double-outlet
right ventricle [119], and a reduction in COUP-TFII expression, a consequence of polymorphisms or
single point mutations of FOXC2, causes varicosity and valve failure in veins [123].
Although the evidence support the notion that COUP-TFII is necessary for the correct function and
development of the cardiovascular system, and even suggest a possible protective action of the receptor,
its overexpression may be deleterious, not only because it may be associated to the development of
human malignancies but also because it may increase the risk of heart diseases. In mice, selective
overexpression of COUP-TFII in the myocardium is a causative agent of dilated cardiomyopathy
followed by heart failure and increased death rate. As previously stated, COUP-TFII is an important
regulator of cell metabolism and alteration of cellular metabolism have been suggested as causative
agents of heart failure [17]. Overexpression of COUP-TFII impairs substrate utilization of fatty acids
and a general reduction of glucose usage, due to altered expression of the glucose transporter Glut-4,
the hexokinase 2 and the 6-phosphofructokinase; moreover PGC-1a, a target of COUP-TFII in adipocytes
differentiation, is downregulated in cardiomyopathy [17,61,124]. Finally, the metabolic changes are
accompanied by increased ROS production, lower ATP output and mitochondria dysfunction due to
a direct inhibition of genes regulating mitochondrial dynamics [17]. Consistent with the regulation
of glucose utilization, COUP-TFII expression is regulated by glucose availability in endothelial cells:
Acute administration of glucose increases COUP-TFII independently from insulin, whereas chronic
administration reduces it. Finally, the silencing of the nuclear receptor in HUVEC cells increases eNOS
and glucose transporters, suggesting a time- and glucose-dependent regulation of the receptor that
could be important in the context of diabetes [125].
4.1.2. COUP-TFII and Diabetes
The association of COUP-TFII and diabetes may be deduced by its role in insulin and glucose
homeostasis and by its role in adipocyte differentiation, which we have already discussed. Specifically,
the interaction of COUP-TFII with PPARγ and β-catenin could have a potential impact in the regulation
of oxidative stress, inflammation and obesity development, which are linked to or are causative agents
of diabetes [51,126]. Noteworthy, the association with diabetes is confirmed by data collected in the
clinical study “Epidemiologic study on the insulin resistance syndrome (DESIR)” [127]. Subjects with
the COUP-TFII polymorphism SNP-rs3743462 have lower blood insulin concentrations due to reduced
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COUP-TFII expression, similarly to what was observed in COUP-TFII +/−mice. This polymorphism is
in a distal conserved region of the COUP-TFII promoter; mechanistically, it determines an increase
binding of COUP-TFII that results in auto-repression of the nuclear receptor and altered insulin
secretion and production [64].
In agreement with its function in vessel identity specification, increased COUP-TFII expression,
paralleled by modifications of SOX18 and Prox1, is associated to brain arteriovenous malformations
(AVM) in humans [128,129]. Anatomically, AVM are a net of dysplastic blood vessels without capillaries
between the venous and arterial compartments. Immunohistochemistry analysis of these vessels
show the contemporary expression of arterial and venous markers in the lesions with an increased
expression of endoglin, indicating that the vessels are not properly differentiated [129]. Endoglin is
a TGF-β co-receptor necessary for angiogenesis [130] and its haplo-insufficiency is associated with
hereditary hemorrhagic Telangiectasia, a hereditary form of vessel malformation; null mice for the
TGF-β co-receptor are defective in vessel differentiation and show ectopic COUP-TFII expression
in the arterial compartment [130], a piece of evidence that strengthen the notion of COUP-TFII as
a causative agent of AVM. Finally, a 15bp genetic deletion of the hinge region, necessary for the
interaction with a friend of GATA2 (FOG2), reduces systolic and diastolic pressure and suggest that
the NR is a determinant of essential hypertension in human [131].
4.1.3. Infertility and Alterations of Mesenchymal Commitment
Alteration of COUP-TFII expression in the stromal compartment is associated with infertility and
alteration of mesenchymal stem cell commitment.
Female and, possibly, male human infertility are linked to COUP-TFII expression [132]. COUP-TFII
is a marker of mesenchymal Leydig stem-like cells [133] and it is a direct regulator of INSL3
hormone produced by Leydig cells [134]. Moreover, COUP-TFII indirectly regulates testosterone
levels influencing the expression of genes involved in testosterone biosynthesis [132,135]. INSL3
determines testicular descent and has been linked to oocyte maturation and male germ survival in
adults; its expression is reduced in human pathologies [136,137]. Pre-puberal COUP-TFII deletion
causes hypogonadism and infertility, due to almost absent spermatozoa [132]; these effects were
largely associated with a reduction of mature Leydig cells and are consistent with a lower testosterone
production but also might be explained by reduced INSL3 production. Interestingly, COUP-TFII
deletion in adult mice has no effect on testosterone levels and Leydig cells appear normal in number,
suggesting that the receptor is dispensable for Leydig function in adults [132]. Recently, a 3 Mb deletion
of the locus containing NR2F2 was described in an SRY 46, XX male with spontaneous male puberty,
further implicating COUP-TFII in sex determination [138].
In female, the occurrence of endometriosis is often a cause of infertility. Endometriotic tissues
exclusively express the aromatase P450 that in eutopic endometrial stromal cells is repressed by
COUP-TFII; aberrant expression of P450 increases estrogen production that, in turn, induces the
expression of prostaglandin and inflammatory cytokines favoring endometriosis progression [139]. In
endometriotic tissues, the P450 COUP-TFII-mediated inhibition is counteracted by SF1 that binds to the
same promoter region [140]. In humans, the expression of COUP-TFII is often reduced in endometriosis
compared to healthy tissues [141]. A possible reason for this reduction is the SF1 indirect regulation of
COUP-TFII. Conversely, to COUP-TFII, SF1 is silenced by methylation in eutopic endometrium but is
highly expressed in endometriosis and hence it might repress COUP-TFII allowing the expression of
P450 [142]. Indeed, Expression of SF1 is sufficient to promote the formation of enlarged glands and to
alter the progesterone–HH–COUP–TFII pathway [142].
In endometrial tissues COUP-TFII regulates angiogenesis, adhesion and inflammation [141].
The inflammatory cytokines IL-1β, TNF-α and TGF-β reduce COUP-TFII by means of the intermediary
miR-302a that targets the 3′-UTR of the NR mRNA; a consequence of the COUP-TFII downregulation is
the activation of COX2 [143] and the hypoxia-dependent expression of angiopoietin [144], two factors
that could promote inflammation and angiogenesis.
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In uterine stroma COUP-TFII is necessary for proper implantation and decidualization. COUP-TFII
expression is regulated by the progesterone–Indian HH axis deriving from epithelial cells. Mesenchymal
cells respond to Indian HH producing BMP that causes decidualization in vivo [145]. Inactivation of the
NR in uterine mesenchymal cells leads to miscarriages during mouse pregnancy caused by improper
placental vascularization [146]. Interestingly, COUP-TFII silencing in human primary endometrial
stromal cells is not sufficient to completely abrogate decidualization but nonetheless alters genes
involved in inflammation, angiogenesis and cell adhesion [141].
As previously discussed, quiescent HSC are substantially COUP-TFII negative but when activated
they start expressing COUP-TFII and losing PPARγ. Sustained activation of HSC brings forth excessive
and uncontrolled deposition of the extracellular matrix that is associated with the development of
liver cirrhosis [54]; similarly, activation of PSC is believed to be the main cause of the desmoplastic
reaction of pancreatic ductal adenocarcinoma (PDAC) [50]. COUP-TFII is highly expressed in cirrhotic
liver and its expression modulates genes involved in wound healing, specifically in angiogenesis,
immunoresponse and extracellular matrix remodeling [54]. Interestingly, angiogenesis is usually
linked to hypoxia, but HSC COUP-TFII-mediated angiogenesis is hypoxia and HIF-1α independent,
but NF-κB dependent, suggesting that COUP-TFII-mediated angiogenesis may be important in the
early phases of the healing response [54].
Finally, COUP-TFII has been also associated with the formation of congenital diaphragmatic
hernia (CDH) and stomach malformations. CHD is a lethal anomaly that occurs in childhood, which
can be caused by partial deletion of chromosome 15q [147]; consistent with this observation, COUP-TFII
KO mice show diaphragmatic defects similar to the Bochdalek-type hernia phenotype and a frameshift
mutation of NR2F2 was recently identified in a patient with CHD [147,148].
COUP-TFII and HH are important determinants of gastric differentiation. Deletions of components
of the HH pathway have been associated with congenital gastrointestinal defects, and loss of HH
expression causes intestinal metaplasia of the stomach [149–151]. Moreover, COUP-TFII null mice in
gastric mesenchymal cells have defects in radial patterning and show epithelial outgrowth; interestingly,
these defects may be recapitulated by treating mice with the HH inhibitor cyclopamine, suggesting that
COUP-TFII is not only a HH target gene but is also essential for HH action in the stomach [152,153].
Mechanistically, HH produced by epithelial cells induces the expression of COUP-TFII in mesenchymal
cells to block the excessive expansion of circular smooth muscle cells and enteric neurons. At the same
time COUP-TFII indirectly inhibits the epithelium proliferation; the mediator of this negative feedback
loop is probably the secreted factor BMP-4, as demonstrated by the fact that the reduction of BMP
signaling increases epithelial proliferation [154,155].
4.2. COUP-TFII in Cancer: The Good Guy and the Bad Guy
The association of COUP-TFII to cancer progression has been widely investigated and it has
received more attention since the demonstration that the NR is a major player in cell differentiation and
cell metabolism. Expression of COUP-TFII and other nuclear receptors (e.g., LXRβ, RARα, REVERBα)
is relatively high in cancer cells tested by high-throughput qPCR; moreover, the receptor forms a cluster
with RXRα, HNF4 (α and β) and PPARγ, reflecting known functional associations and is relatively
near to ERα, who is implicated in breast cancer progression (see below for details) [138]. Interestingly,
COUP-TFII negatively correlates with the resistance to some chemotherapy agents, especially to
derivatives of microtubule-targeting drugs (e.g., Taxol or colchicine), pointing to a putative association
with a cytoskeleton organization and EMT [156].
Nonetheless, reflecting the number of putative and demonstrated functions, as well as the ever
increasing interactome of COUP-TFII, it is not entirely surprising that a consensus is not reached on its
function and we may differentiate among tumors where COUP-TFII might act as onco-suppressor or
as oncogene, with some gray areas in-between (Table 1).
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Table 1. COUP-TFII in cancer: role and molecular effects.
Cancer Role Ref. Effects
Colorectal cancer Onco-suppressor (?) [157,158] ↑survival rate
Oncogene (?) [159–162] ↑risk of metastasis
↓overall survival
↑invasion
↑EMT
Pancreatic cancer Oncogene [163] ↓survival rate
↑invasiveness
↑anchorage-independent
cells growth
↑neoangiogenesis
Gastric cancer Onco-suppressor (?) [164,165] ↓proliferation
↓migration
↓invasiveness
↓cell growth
↓metastasis
↑survival rate
Oncogene (?) [166] negative prognostic role
Prostate cancer Oncogene [167–172] ↑tumor cell growth
↑proliferation
↑metastatic potential
↑invasion
Renal cancer Oncogene [173,174] ↓survival rate
↑proliferation
↓apoptosis
Breast cancer Oncogene(?) [95] ↓survival rate
↑lymph node metastasis
Onco-suppressor(?) [175–182] ↑effects of Tamoxifen(TAM)
↓EMT
↓proliferation
4.2.1. The Gastrointestinal Cancers: Mostly an Oncogene
In the gastrointestinal tract (i.e., intestine, pancreas and stomach) COUP-TFII acts both as
an oncogene and as an onco-suppressor.
Despite the in vitro and in vivo results on animal models, there is no consensus on COUP-TFII
in primary colorectal cancer, and there are probably too few data to reach a meaningful conclusion.
In 2009, Shin et al. [157] reported that COUP-TFII-expressing Korean patients have increased overall
survival compared to non-expressing individuals, although borderline significant. The same group
confirmed these results in 2017: Studying LXR, they found out that its expression and the absence of
COUP-TFII were both negative prognostic factors and were associated to shorter overall survival [158].
However, two different groups reported that high expressing COUP-TFII patients, compared to low
expressing patients, have increased risk of metastasis and lower overall survival [159,160]. Interestingly,
in primary tumors COUP-TFII correlates with SNAIL1 and SMAD4 and in cell lines with the loss of
SMAD7 [159–161]. SNAIL1 is a transcription factor usually expressed during EMT; its expression has
been demonstrated to induces EMT in gastric cancer [183] although it may direct the cells towards a low
proliferating phenotype trough the β-catenin-LEF1 complex [184]. SMAD7 instead is the only inhibitor
member of the SMAD proteins that mediate the action of EMT-inducers TGF-β and BMP [185–187].
These observations agree with in vitro experiments and animal models of colorectal cancer, where
COUP-TFII facilitates cell invasion and EMT [159,161,188]. COUP-TFII −/−mice in the colon mucosa,
treated with DMH/DSS to induce colon cancers, have lower liver metastasis compared to wild-type
mice. This effect was further investigated in vitro in human cancer cells where TGF-β-mediated
EMT was reduced (as demonstrated by an increase in ZO, membrane β-catenin and E-cadherin) after
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silencing the NR: The culprit was found in the reduction of SNAIL1, whose expression is directly
regulated by COUP-TFII [159]. Apparently, COUP-TFII is at the center of a miRNA network that
elegantly explain the loss of EMT. MiR-382 is an onco-suppressor in non-small-cell lung, ovarian,
prostate and esophageal cancers [189–192], and it is downregulated in colorectal cancer where it inhibits
tumor metastasis, blocking SP1, and sensitizes cancer cells to chemotherapy [193,194]. Interestingly,
COUP-TFII potentiates the action of SP1 in angiogenesis and development [92,94], recognizing SP1
response elements and miR-382 directly binds COUP-TFII 3′-UTR, knocking down the receptor, and
hence downregulates two transcription factors that are demonstrated to synergize and induce EMT.
Besides being regulated by miRNAs, COUP-TFII is also a miRNA-regulatory factor, specifically of
miR-21 and miR-34a in colon cancer [161,162]. MiR-21 inhibits the phosphatase and tensin homologue
(PTEN) and programmed cell four, and it is up-regulated in cancer compared to adjacent tissues; its
circulating levels have been proposed as a potential biomarker in colorectal cancer, together with
other miRNAs. Moreover, miR-21 might increase prostaglandin E2 levels (a potent mediator of
inflammation), inhibiting 15-hydroxyprostaglandin dehydrogenase. MiR-34a is a tumor suppressor
miRNA: In colorectal cancer its expression is usually downregulated, often because of TGF-β action
or long non-coding RNA acting as sponge for the miRNA [195,196]. Key features of miR-34a are the
inhibition of cell migration and its chemosensitizer role in colorectal cancer [197,198]. COUP-TFII
directly induces the expression of miR-21 in TGF-β-treated cells, resulting in the downregulation of
SMAD7 whereas it reduces miR-34a [161,162]; hence, modulating miR-21a and miR-34a, COUP-TFII
strengthen its action as tumor oncogene and induces EMT in colorectal cancer.
Although COUP-TFII expression in pancreatic tissue was reported long ago [199], its implication
in PDAC has only recently been demonstrated [163,199]. In pancreatic cancer patients COUP-TFII
correlates with a worse prognosis and lower survival; in vitro and in vivo experiments revealed that
COUP-TFII promotes invasiveness and anchorage-independent growth of PDAC cells, and it plays
a fundamental role in neoangiogenesis by directly modulating VEGF-C [163].
There are limited and conflicting data on COUP-TFII in gastric cancer. Feng et al. [166] have
hypothesized that COUP-TFII might be an oncogene given its significant up-regulation in primary
cancers compared to normal tissues and the overall shorter survival of patients with elevated COUP-TFII
expression. However, different pieces of evidence suggest the opposite. Indeed, downregulation
of COUP-TII and up-regulation of HNF4α has been linked to the development of gastric intestinal
metaplasia, a frequent precancerous lesion of the stomach, indicating a protective role of the NR in
gastric cancer progression [164]. In line with this finding, COUP-TFII is more expressed in normal gastric
mucosa cells (GES-1) compared with gastric cancer cells and gastric carcinoma tissues. Moreover, GES-1
cells with COUP-TFII knocked down have increased proliferation and invasiveness while COUP-TFII
overexpression in xenograft tumor models reduces the tumor burden [165]. Finally, confronting the
pathological data from 80 gastric cancer patients obtained from the Oncomine database, Ding et al.
demonstrated that high expression of COUP-TFII correlates with increased survival [165], in stark
contrast with the results of Feng et al. [166]. It is conceivable that this discrepancy arises from the
use of different databases, the use of different selection criteria of the study population and the probe
tested. Given the in vitro and in vivo results we may hypothesize that COUP-TFII is probably an
onco-suppressor in the gastric cancer, but more experiments need to be done to fully understand its
action in this tumor.
4.2.2. The Uncertainty of COUP-TFII in the Breast Cancer
Expression of COUP-TFII in primary breast cancer has been reported in 47% to 59% of cases
analyzed by immunohistochemistry [95,175]. Whereas an initial report suggested a positive correlation
between COUP-TFII and tumor progression, specifically with a worse outcome and lymph node
metastasis [95] (who were linked to VEGF-C expression), recent evidence have challenged this idea,
suggesting that COUP-TFII may play different roles during breast cancer progression [175–179].
The expression of the estrogen receptor α (ERα) is one of the main discriminants in the choice of breast
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chemotherapy. Interestingly, COUP-TFII expression is positively associated with ERα expression and
it is reduced in endocrine-resistant cell lines, independently of ERα expression. Indeed, tamoxifen
resistant (TAM-R) MCF-7-derived cells are ERα positive but low-expressing COUP-TFII cells and
re-establishing COUP-TFII expression in TAM-R have no effects per se but enhances the antiproliferative
response to 4-OHT. Interestingly, reducing the expression of COUP-TFII in MCF-7 cells transforms
4-OHT from an antagonist to an agonist of cell proliferation. These phenotype changes are also reflected
in the expression of progesterone receptor (PR) and pS2, two known targets of ERα, suggesting that the
COUP-TFII role is more complex and the final response to its expression could arise from integrating
different stimuli.
ERα controls COUP-TFII expression, given that mRNA of the latter increases after either
overexpression of ERα or treatment with E2, but not in TAM-R cells [175]. Nonetheless, regulation of
COUP-TFII expression is only partially associated with an ERα direct transcription activity and requires
the presence of a functional MAPKs cascade [200]; hence, it could be dependent on the presence of
growth factors or to a transcription-independent ERα activity, both resulting in activation of MAPK.
Using genomic localization maps, Erdos and Balint [201] have recently mapped the COUP-TFII cistrone,
demonstrating its co-localization with master transcription factors, namely ERα in MCF-7 cells, HNF4
in HepG2 and GATA-binding factors in K562 cells [201]. Co-presence of ERα and COUP-TFII marks
the promoter area as an active enhancer and suggests that the orphan receptor might mediated the
effects of the hormone. Similar results were reached by a different group almost at the same time,
highlighting the importance of COUP-TFII in mediating ERα transcription activity, and extending
the interaction of COUP-TFII to pioneer factors FoxA1 and GATA3 whose co-presence is apparently
necessary for creating a strong enhancer region accessible to ERα [177].
Several pieces of evidence suggest that COUP-TFII could partially act like a tumor-suppressor.
First, its expression increases p21/WAF and cyclin D1 delaying the transition trough the G2/M
phase [180]; second, COUP-TFII interacts with nucleolin and it is required for the expression of RARB2,
a known tumor suppressor [175]; lastly, these results are confirmed by the observation that COUP-TFII
is negatively associated with EMT transition induced by TGF-β, and to the resistance to chemotherapy
and to changes in E-cadherin and Slug, the latter two being markers of EMT [179]. Downregulation
of the NR in tamoxifen-resistant cells is probably linked to epigenetic modifications; treatment with
5-aza-2′-deoxycitidine (AZA), a demethylating agent, or with the deacetylase inhibitor trichostatin,
increases COUP-TFII expression in TAM-R cells [176]. Among the 7 GpC islands located in the NR2F2,
the most methylated is located on the first exon. The increased methylation observed in vitro is also
confirmed in human breast tumors compared to healthy breasts.
The acquisition of hormone resistance has been associated to an increased expression of NF-κB,
a known modulator of inflammation, redox and metabolic status, and competitively associated with
several nuclear receptors [126]. As in other organs and pathologies, COUP-TFII inhibits NF-κB
activation and down-targets expression, co-immunoprecipitating with RelB and NF-κB in Mcf-7 cells.
Furthermore, COUP-TFII and NF-κB status are inversely correlated in patients, and their association
has been suggested as a possible explanation of acquired hormone resistance following COUP-TFII
downregulation [181].
An interesting feature of breast cancer progression is vascular trans-differentiation, or vascular
mimicry, i.e., the ability of epithelial tumor cells to convert into endothelial-like cells, which initially
facilitates the local tumor growth and later its spreading [202]. In breast cancer, the expression
of endothelial markers in tumor cells can be induced by retinoic acid that noteworthy reduces cell
proliferation. Interestingly RA-treated cells show activation of COUP-TFII and COUP-TFII KO prevents
the formation of vessel-like structure in Matrigel but has no effect on VE-cadherin expression and
does not influence cell fusion. Hence, apparently, although COUP-TFII is expressed and required for a
specific step of vascular mimicry, it is conceivable that it could mediate the RA-induced reduction of
cell proliferation [182].
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4.2.3. Prostate and Renal Cancers
Recent studies revealed that in prostate cancer (PC) and in renal cell carcinoma (RCC) COUP-TFII
is a putative oncogene [167–174,203].
COUP-TFII expression in primary PC is greater than in healthy prostate epithelium, with the NR
amount correlating to an increased metastatic potential and reduced recurrence-free survival [167–169].
However, overexpression of COUP-TFII is not sufficient to induce tumor development but it potentiates
the metastatic capacity in the indolent PTEN −/− mouse model of PC [169]. In these mice the loss
of PTEN is usually accompanied by the activation of the TGF-β pathway, which induces the growth
of an extracellular barrier that restricts prostate cancer growth and progression [169,203]. While
TGF-β apoptotic and cytostatic signals are counteracted by the activation of AKT and mTOR in the
PTEN −/− background, to become metastatic PC cells requires the overexpression of COUP-TFII.
Indeed, in vivo experiments show that NR overexpression in PTEN −/− prostatic epithelium leads
to increased cancer cell proliferation and invasiveness; these effects are a consequence of the direct
binding and sequestration of SMAD4 by COUP-TFII that causes the loss of the TGF-β signal and
the reduction of TGF-β-induced growth barrier [169]. Furthermore, the association of the NR with
metastasization is also underscored by the finding that COUP-TFII expression positively correlates
with p-mTOR expression and both are predictors of increased lymphangiogenesis and lymph node
metastasis in PC primary samples [170]. The link with mTOR points to a role of COUP-TFII in the
regulation of PC metabolism. Indeed, the increased expression of COUP-TFII in PC cells induces
a reduction of the mitochondrial pyruvate carrier 1 (MPC1) expression. MPC1 is a regulator of cancer
cells metabolism, which together with MCP2 forms a complex capable of regulating pyruvate transport
within mitochondria [172]; the reduction of MPC1 mediated by COUP-TFII has a negative impact on
mitochondrial pyruvate import and induces the cells to use different intermediate substrates for the
TCA cycle and at the same time increases glycolysis, promoting tumor growth and invasion of prostate
cancer cells [172]. Finally, COUP-TFII is repressed by miR-382, 101 and 27a, whose expression is often
reduced in PC [171,192]. The knock-down of these miRNAs increases PC proliferation and invasiveness;
mechanistically, it allows the expression of EMT markers SNAIL and matrix metalloproteinase 2 and
increases cell proliferation and invasiveness in a COUP-TFII-dependent manner. Moreover, miR-101
and miR-27a negatively regulate the resistance to the chemotherapy drug enzalutamide by indirectly
downregulating the expression of the COUP-TFII down-targets FoxM1 and centromere protein F
(CENPF) [171].
In RCC, the most common type of kidney cancer, COUP-TFII expression is considerably higher
in cancer tissues and cancer cell lines than in healthy counterparts. Moreover, elevated levels of
COUP-TFII correlate with a poor prognosis and are an indicator of poor survival [173,174]. The
COUP-TFII oncogenic role in RCC may be due to the regulation of the cell cycle and apoptosis. In fact,
in vitro and in vivo experiments have shown that COUP-TFII silencing inhibits cancer cell proliferation,
reducing the number of cells in the S-phase and inducing cell apoptosis, increasing the expression of
pro-apoptotic factors, including cytochrome C, BCL2 Associated X (BAX) and BRCA1 [173,174].
5. Conclusions
The orphan nuclear receptor COUP-TFII is clearly implicated in embryogenesis and organogenesis
as demonstrated by the lethal KO phenotypes [16]. In adults its expression is widespread with
peak expression in cells of mesenchymal origin. Accumulating pieces of evidence show that it is
implicated in tissue homeostasis and maintenance and it is a major regulator of cell differentiation and
angiogenesis [16,20,46,54,55].
The importance of COUP-TFII in endothelial identity is well documented; the choice of arterial
versus venous fate is a result of a cross-talk between Notch and COUP-TFII signaling, while the
interactions of Brg1, Prox1 and COUP-TFII are central for lymphatic development [96,100,111,204].
The ability to direct angiogenesis is paralleled by its role in mesenchymal cell differentiation and
point to a role of the NR in regulating the cells micro-environment with evident implications for
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several pathologies [45,54,74,95,117,128,132,146]. Indeed, the NR expression (or the absence thereof) is
associated with the unfavorable progression of malignancies in several organs [157,163,165,167,173,181];
besides, COUP-TFII is linked to pathologies considered cancer risk factors, such as diabetes or
cirrhosis [54,64].
Association with diabetes point to its role in the metabolic machinery: COUP-TFII is a regulator
of adipocyte differentiation and lipid metabolism interacting or regulating other transcription factors,
mainly of the PPAR family. Moreover COUP-TFII is implicated in glucose homeostasis in metabolically
active tissues where increased expression of the receptor leads to reduced metabolism, higher ROS
production and mitochondria disfunctions [17].
Still, there are several aspects of COUP-TFII physiology that need to be addressed by
future researches.
First, it is apparent that COUP-TFII action is often context dependent, hence the identification of
COUP-TFII partners, and the mechanisms of interactions with them could help shed light on some of
the more complicated and difficult-to-explain results (e.g., the role in adipogenesis or the different
roles of COUP-TFII in breast cancer).
Second, for historical reasons the research on COUP-TFII is essentially focused on the role of the
canonical isoform, but new isoforms of COUP-TFII have been recently discovered. The lack of the
DBD in these isoforms suggest that they might act with still unknown mechanisms. Interestingly, they
also could be a different gene, or at least produced by an alternative promoter.
Third and finally, the discovery of specific and safe agonists and antagonists is mandatory for
translational research. Even if COUP-TFII could easily be a true orphan receptor, the idea of COUP-TFII
modulation for treatment is nonetheless absolutely of interest, although it is currently hampered by
the lack of specific ligands. Several steps forward have been recently made with the discovery that
naphthol compounds may modulate the NR, essentially inducing its degradation, but the research of
COUP-TFII ligands is still in its infancy. Although the inhibition of COUP-TFII could be of interest for
the treatment of some cancers or pathologies like cardiomyopathies, other pathologies, like infertility,
could get therapeutic benefits from the use of COUP-TFII agonists.
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